Literature DB >> 23557113

Recent developments in texaphyrin chemistry and drug discovery.

Christian Preihs1, Jonathan F Arambula, Darren Magda, Heeyeong Jeong, Dongwon Yoo, Jinwoo Cheon, Zahid H Siddik, Jonathan L Sessler.   

Abstract

Texaphyrins are pentaaza expanded porphyrins with the ability to form stable complexes with a variety of metal cations, particularly those of the lanthanide series. In biological milieus, texaphyrins act as redox mediators and mediate the production of reactive oxygen species (ROS). In this review, newer studies involving texaphyrin complexes targeting several different applications in anticancer therapy are described. In particular, the preparation of bismuth and lead texaphyrin complexes as potential α-core emitters for radiotherapy is detailed, as are gadolinium texaphyrin functionalized magnetic nanoparticles with features that make them of interest as dual-mode magnetic resonance imaging contrast agents and as constructs with anticancer activity mediated through ROS-induced sensitization and concurrent hyperthermia. Also discussed are gadolinium texaphyrin complexes as possible carrier systems for the targeted delivery of platinum payloads.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23557113      PMCID: PMC3963820          DOI: 10.1021/ic400226g

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  37 in total

1.  Expanded Porphyrins and Their Heterologs.

Authors:  Ayub Jasat; David Dolphin
Journal:  Chem Rev       Date:  1997-10-01       Impact factor: 60.622

Review 2.  Strategies for increasing the sensitivity of gadolinium based MRI contrast agents.

Authors:  Peter Caravan
Journal:  Chem Soc Rev       Date:  2006-05-03       Impact factor: 54.564

3.  Bismuth and lead hanging-carboxylate porphyrins: an unexpected homobimetallic lead(II) complex.

Authors:  Zakaria Halime; Mohammed Lachkar; Thierry Roisnel; Eric Furet; Jean-François Halet; Bernard Boitrel
Journal:  Angew Chem Int Ed Engl       Date:  2007       Impact factor: 15.336

4.  Linear and pre-organized carboxylic acid picket porphyrins as bismuth chelators.

Authors:  Zakaria Halime; Mohammed Lachkar; Eric Furet; Jean-François Halet; Bernard Boitrel
Journal:  Inorg Chem       Date:  2006-12-25       Impact factor: 5.165

Review 5.  Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance.

Authors:  Z H Siddik; G S Hagopian; G Thai; S Tomisaki; T Toyomasu; A R Khokhar
Journal:  J Inorg Biochem       Date:  1999-10       Impact factor: 4.155

6.  In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer.

Authors:  R A Miller; K Woodburn; Q Fan; M F Renschler; J L Sessler; J A Koutcher
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-11-01       Impact factor: 7.038

Review 7.  Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.

Authors:  Michelle Martinez-Rivera; Zahid H Siddik
Journal:  Biochem Pharmacol       Date:  2011-12-26       Impact factor: 5.858

8.  The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog.

Authors:  Guangan He; Jian Kuang; Abdul R Khokhar; Zahid H Siddik
Journal:  Gynecol Oncol       Date:  2011-05-18       Impact factor: 5.482

9.  Preclinical evaluation of gadolinium (III) texaphyrin complex. A new paramagnetic contrast agent for magnetic resonance imaging.

Authors:  S W Young; M K Sidhu; F Qing; H H Muller; M Neuder; G Zanassi; T D Mody; G Hemmi; W Dow; J D Mutch
Journal:  Invest Radiol       Date:  1994-03       Impact factor: 6.016

10.  Late first-row transition-metal complexes of texaphyrin.

Authors:  Sharon Hannah; Vincent Lynch; Dirk M Guldi; Nikolay Gerasimchuk; Charles L B MacDonald; Darren Magda; Jonathan L Sessler
Journal:  J Am Chem Soc       Date:  2002-07-17       Impact factor: 15.419

View more
  6 in total

1.  Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches.

Authors:  Nikki A Thiele; Justin J Wilson
Journal:  Cancer Biother Radiopharm       Date:  2018-06-11       Impact factor: 3.099

2.  Porphyrinoid Drug Conjugates.

Authors:  Jonathan F Arambula; Jonathan L Sessler
Journal:  Chem       Date:  2020-07-09       Impact factor: 22.804

3.  Texaphyrins and water-soluble zinc(II) ionophores: development, mechanism of anticancer activity, and synergistic effects.

Authors:  Christian Preihs; Darren J Magda; Jonathan L Sessler
Journal:  Bioinorg React Mech       Date:  2013-12-01

4.  Dietary Restriction and Epigenetics: Part I.

Authors:  Gavin Yong-Quan Ng; David Yang-Wei Fann; Dong-Gyu Jo; Christopher G Sobey; Thiruma V Arumugam
Journal:  Cond Med       Date:  2019-12

5.  Cell-Penetrating Protein/Corrole Nanoparticles.

Authors:  Matan Soll; Tridib K Goswami; Qiu-Cheng Chen; Irena Saltsman; Ruijie D Teo; Mona Shahgholi; Punnajit Lim; Angel J Di Bilio; Sarah Cohen; John Termini; Harry B Gray; Zeev Gross
Journal:  Sci Rep       Date:  2019-02-19       Impact factor: 4.379

Review 6.  H2O2-Driven Anticancer Activity of Mn Porphyrins and the Underlying Molecular Pathways.

Authors:  Ines Batinic-Haberle; Artak Tovmasyan; Zhiqing Huang; Weina Duan; Li Du; Sharareh Siamakpour-Reihani; Zhipeng Cao; Huaxin Sheng; Ivan Spasojevic; Angeles Alvarez Secord
Journal:  Oxid Med Cell Longev       Date:  2021-03-15       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.